MASS SPECTROMETER SYSTEM AND ACCESSORIES

这份提案是为了购买一台气相色谱仪/质谱仪 光谱/数据系统能够在这两种化学品中运行 电离、负离子模式(GC/NICI-MS)和电子碰撞电离， 正离子模式。这台仪器将由五名调查人员使用 他们得到了国家卫生研究院的支持。其中四个 需要支持的项目目前由美国国立卫生研究院和一个 代表着资金悬而未决的新方向。这个 研究人员和项目如下：(1)Alan S.Nies，M.D.(R01 HL 21308)“前列腺素在肿瘤局部控制中的作用” 这个建议是为了研究前列环素在体内的作用。 调节降压药的作用。前列环素生产 将通过尿液中主要酶的排泄量进行评估 前列环素代谢物Dior-6-keto-PGF1α的测定 GC/NICI-MS这项建议的第二部分是调查肾脏 血小板活化因子的释放，将用GC/NICI-分析- (2)Duane C.Bloedow，Ph.D.(R01 GM 29543)“肝脏清除 烧伤患者的用药情况。这项建议是为了调查 模型化合物利多卡因和安替比林在烧伤中的药代动力学 病人。分析需要同时给药[2H2] 口服利多卡因，静脉注射未标记的形式。分析了几种 利多卡因和安替比林及其代谢物将使用质谱学。 (3)Keith L.Clay，Ph.D.(P01 HL 34303)“乙醚类脂、二十烷类化合物和 肺细胞病理生理学。这项建议要求GC/NICI-MS用于 血小板活化因子和二十烷类化合物的极低灵敏度测定 浓度。(4)Joseph Gal，Ph.D.(R01 HL/GM 34789)“立体专门化 新的抗心律失常药物的分析。这项建议是为了发展GC/MS 血清中美西律对映体的顺序分析方法 确定美西律(A)时处置的立体化学方面 外消旋混合物)。(5)John G.Gerber，M.D.(R01 DK 38504) 《胃组胺体内释放调节剂》。这个项目考察了 犬胃组胺释放的控制因素及相关因素 要求使用GC/NICI-MS分析组胺和 血浆中甲基组胺的浓度为50-100pg/ml。 用于分析大量样品的仪器，由 这五个项目是有限的。这些项目不能以一种 不需要所请求的仪器的最佳速率。伊利诺伊大学 科罗拉多州致力于质谱学和现有的质谱仪 光谱分析资源中心提供培训服务 就所需设备的维护问题进行咨询。 对于这项提议，大学承诺提供资金用于翻修 所要求的仪器的空间和维护，以确保其 最佳利用率。

This proposal is for the purchase of a gas chromatography/mass spectrometry/data system that is capable of operating in both chemical ionization, negative ion mode (GC/NICI-MS) and electron impact ionization, positive ion mode. This instrument will be utilized by five investigators who are supported by the National Institutes of Health. Four of the projects to be supported are currently funded by the NIH and one represents a new direction for which funding is pending. The investigators and projects are as follows: (1) Alan S. Nies, M.D. (R01 HL 21308) "The role of Prostaglandins in the Local Control of the Circulation". This proposal is to investigate the role of prostacyclin in mediating the effects of antihypertensive drugs. Prostacyclin productions in humans will be assessed by the urinary excretion of the major enzymatic metabolite of prostacyclin, dinor-6-keto-PGF 1alpha as measured by GC/NICI-MS. The second part of this proposal is to investigate the renal release of platelet activating factor, which will be analyzed by GC/NICI- MS. (2) Duane C. Bloedow, Ph.D. (R01 GM 29543) "Hepatic Clearance of Drugs in Burn Patients". This proposal is to investigate the pharmacokinetics of model compounds, lidocaine and antipyrine, in burn patients. The analysis requires the simultaneous administration of [2H2] lidocaine orally, and an unlabelled form intravenously. The analyses of lidocaine and antipyrine and their metabolites will use mass spectrometry. (3) Keith L. Clay, Ph.D. (P01 HL 34303) "Ether Lipids, Eicosanoids, and Lung Cell Pathophysiology". This proposal requires GC/NICI-MS for sensitive assays of platelet activating factor and eicosanoids at very low concentrations. (4) Joseph Gal, Ph.D. (R01 HL/GM 34789) "Stereospecific Analysis of new Antiarrhythmic Agents". This proposal is to develop GC/MS methodology for the analysis of mexiletine enantiomers in serum in order to determine the stereochemical aspects of disposition when mexiletine (a racemic mixture) is administered. (5) John G. Gerber, M.D. (R01 DK 38504) "Modulators of Gastric Histamine Release in vivo". This project examines the factors controlling the release of gastric histamine in the dog and requires the use of GC/NICI-MS for the assay of histamine and methylhistamine in plasma in levels of 50-100pg/ml. The available instrumentation for analyses of large numbers of samples as generated by these five projects is limited. These projects cannot proceed at an optimal rate without the instrumentation requested. The University of Colorado has a commitment to mass spectrometry and the existing Mass Spectrometry Resource Center has offered its services for training personnel and for consultation on maintenance of the requested equipment. For this proposal, the University has committed funds for renovation of space and maintenance of the requested instrument in order to ensure its optimal utilization.